SGLT2 Inhibition in the Comorbid CKD patient

Published: 22 February 2022

  • Views:

    Views Icon 34536
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


At e-SPACE CRM 2022 clinical data was analysed through a practical lens to address questions around SGLT2 inhibitor use in CKD.


Explore the data-supported discussion of the treatment landscape for patients with CKD, and other comorbidities. The inciteful conversation is led by Dr Muthiah Vaduganathan (Chair) and Professor Mustafa Arici.

This symposium was endorsed by University of Groningen and supported by an unrestricted educational grant from AstraZeneca.

This educational symposium will increase delegates' understanding of:

  • SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
  • Data supporting the cardiorenal efficacy of SGLT2 inhibition in comorbid patients with CKD
  • How clinical data from SGLT2 inhibitor trials should be applied in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists

More from this programme

Part 1

Welcome and Introductions

Overview of the symposium agenda followed by a patient case with CKD, mild HFrEF, and no T2D will be presented with a view of exploring how SGLT2 inhibitor therapy could slow CKD progression and manage HF simultaneously.

Part 2

Clinical data through a practical lens

A discussion session featuring supporting data around the use of SGLT2 inhibitor therapy for slowing CKD progression and managing HF in the patient case.

Part 3

Discussion and Q&A

A discussion and Q&A with Dr Muthiah Vaduganathan and Prof Mustafa Arici.

Faculty Biographies

Muthiah Vaduganathan

Muthiah Vaduganathan

Consultant Cardiologist

Dr Vaduganathan is a Cardiologist and clinical trialist at Brigham and Women’s Hospital and Harvard Medical School. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He is a co-chair of a Heart Failure Collaboratory committee focused on improving future clinical trials in heart failure, and serves on the planning committee of the Global CardioVascular Clinical Trialists Forum. He is a Section Editor of the Fellows-in-Training / Early Career section of JACC, Associate Editor of JACC Heart Failure, and serves on the editorial board of the European Journal of Heart Failure. His research focuses on drug development, clinical trials, and implementation of cardio-renal-metabolic therapies, and he has authored or co-authored more than 500 peer-reviewed publications. He participates on study leadership and on committees of ongoing advanced-phase trials in cardiometabolic medicine and heart failure.

View full profile